家族性肺纤维化病史可预测间质性肺疾病患者更差的生存
研究在德克萨斯大学西南医学中心和加州大学戴维斯分校连续入组间质性肺疾病(ILD)患者,系统采集家族史并按特发性肺纤维化(IPF)与非IPF分层。结果显示,自报家族性肺纤维化者无移植生存更差,家族性非IPF ILD的预后接近散发性IPF。
要点
- 自报家族性肺纤维化与IPF及非IPF ILD患者无移植生存下降相关。
- 家族性非IPF ILD的死亡或移植风险与散发性IPF相近。
- 在基因检测普及前,应将家族史纳入ILD风险分层。
核心结论
- 患者自报的家族性肺纤维化可预测IPF和非IPF ILD患者无移植生存降低。
- 家族性非IPF ILD的生存接近散发性IPF,应考虑早期干预。
研究设计与样本
- 连续入组同意临床注册登记的ILD患者,系统采集家族史。
- 按IPF与非IPF ILD诊断分层,并按有无家族性肺纤维化亚分层。
- 采用多水平混合效应Cox比例风险回归比较无移植生存。
- 共纳入1262例患者,其中IPF 534例(42%),非IPF ILD 728例(58%)。
主要发现
- 非IPF ILD中,18.5%为结缔组织病,15.6%为慢性过敏性肺炎,23.5%为不可分类ILD。
- IPF患者中134例(25.1%)报告家族性肺纤维化,非IPF ILD患者中90例(12.4%)报告。
- 家族性IPF较散发性IPF死亡或移植风险增加80%(HR 1.8;95%CI 1.37-2.37;P<.001)。
- 家族性非IPF ILD较散发性非IPF ILD风险增加两倍(HR 2.08;95%CI 1.46-2.96;P<.001)。
- 家族性非IPF ILD与散发性IPF的结局风险无差异(HR 1.27;95%CI 0.89-1.84;P=.19)。
临床怎么用
- 对ILD患者应常规采集家族性肺纤维化病史并用于风险分层。
- 家族性非IPF ILD患者预后类似散发性IPF,可考虑早期干预。
局限性
- 家族性肺纤维化基于患者自报,未常规进行基因检测确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A number of genetic markers linked to familial pulmonary fibrosis predict differential survival in interstitial lung disease (ILD) patients. Although genetic testing is not performed routinely for ILD, family history commonly is obtained and may inform outcome risk. RESEARCH QUESTION: Does survival vary between patients with and without self-reported familial pulmonary fibrosis? METHODS: Family history was acquired systematically for consecutive ILD patients who consented to clinical registry enrollment at the University of Texas Southwestern and the University of California at Davis. Patients were stratified by idiopathic pulmonary fibrosis (IPF) and non-IPF ILD diagnosis and were substratified by presence or absence of familial pulmonary fibrosis, defined as one or more additional affected family members. Transplant-free survival was compared using multilevel, mixed-effects Cox proportional hazards regression. RESULTS: Of the 1,262 patients included, 534 (42%) had IPF ILD and 728 (58%) had non-IPF ILD. Of those with non-IPF ILD, 18.5% had connective tissue disease, 15.6% had chronic hypersensitivity pneumonitis, and 23.5% had unclassifiable ILD. Familial pulmonary fibrosis was reported in 134 IPF ILD patients (25.1%) and 90 non-IPF ILD patients (12.4%). Those with familial IPF showed an 80% increased risk of death or transplantation compared with those with sporadic IPF (hazard ratio [HR], 1.8; 95% CI, 1.37-2.37; P < .001), whereas those with familial non-IPF ILD showed a twofold increased risk compared with their counterparts with sporadic disease (HR, 2.08; 95% CI, 1.46-2.96; P < .001). Outcome risk among those with familial non-IPF ILD was no different than for those with sporadic IPF ILD (HR, 1.27; 95% CI, 0.89-1.84; P = .19). INTERPRETATION: Patient-reported familial pulmonary fibrosis is predictive of reduced transplant-free survival in IPF and non-IPF ILD patients. Because survival among patients with familial non-IPF ILD approximates that of sporadic IPF ILD, early intervention should be considered for such patients. Until clinical genetic testing is widely available and provides actionable results, family history should be ascertained and considered in risk stratification.
引用
- Cutting CC, Bowman WS, Dao N, et al. Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease. Chest. 2021. PMID: 33484728. doi:10.1016/j.chest.2021.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。